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Abstract
Background: In July 2003 the National Institute of
Clinical Excellence (NICE) issued guidelines on the
management of congestive heart failure.  We set out to assess
the management of congestive heart failure in St. Luke’s
Hospital (SLH), Malta.
Methods: The files of patients admitted to SLH during
the month of January 2002 were retrieved.  Eligible patients
were those with a history of congestive heart failure.  Patients
who had passed away by the time of the audit or whose files
were untraceable were excluded from the audit.  Data from the
file pertaining to that specific admission was entered in a pre-
prepared data sheet.  This includes demographic data about
the patient, investigations performed to reach diagnosis and
assess severity, pharmacological and non-pharmacological
management of heart failure, and planned follow-up at time of
discharge.
Results: The management of 97 patients was assessed.
All patients with a clinical diagnosis of congestive heart failure
had an electrocardiogram, chest X-ray, urea, electrolytes and
creatinine estimation and a full blood count.  Regarding the
other tests recommended by NICE, echocardiography was
performed in 28% of patients, serum glucose was assayed in
87%, liver function tests in 36%, thyroid function tests in 24%,
urinalysis in 13%, lipids in 8% and spirometry in none. Two
per cent of patients had lifestyle modification advice
documented in the file.  Pharmacological treatment consisted
of diuretics (98%), ACE inhibitors (71%), angiotensin II
receptor blockers (4%), ß-blockers (9%), spironolactone (12%)
and digoxin (25%).
Conclusions: There is still scope for improvement in the
management of congestive heart failure locally.
Introduction
Chronic heart failure is known to be a major public health
problem in industrialised countries with ageing populations.
Its prognosis has been equated with that of the more common
malignancies.  The management of heart failure requires
frequent, prolonged, and costly admissions to hospital.1,2
Despite this, studies have repeatedly shown that heart
failure is generally not managed optimally.3,4  Effective
therapies are underprescribed and patients are often non-
compliant.3,4  Lifestyle modifications such as exercise training
and rehabilitation, advice on smoking and alcohol
consumption or vaccination against influenza and
pneumococcal disease are often ignored.3,4 Should medical
care improve, many hospital admissions would prove
avoidable.3-5
In July 2003 the National Institute of Clinical Excellence
(NICE) issued guidelines6 on the management of congestive
heart failure. NICE is an independent organisation within the
NHS responsible for providing national guidance on treatment
and care in the UK.  We set out to assess the management of
congestive heart failure in St. Luke’s Hospital (SLH), Malta
using the NICE guidelines as the standard for ideal quality of
care in order to identify areas of potential improvement.
NICE guidelines
The key recommendations from the NICE guidelines are
summarized in this section.
Diagnosis
• The basis for the historical diagnoses of heart failure
should be reviewed according to the algorithm outlined
in Figure 1.
• Doppler 2D echocardiographic examination should be
performed to exclude significant valvular heart disease,
assess the systolic (and diastolic) function of the (left)
ventricle and detect intracardiac shunts.
Treatment (Figure 2)
• Lifestyle modification should be enforced in all patients.
This should address exercise promotion, smoking
cessation, modification of alcohol intake and vaccination.
• All patients with heart failure due to left ventricular
systolic dysfunction should be considered for treatment
with an ACE inhibitor.
• Beta blockers licensed for use in heart failure should be
initiated in patients with heart failure due to left
ventricular systolic dysfunction after diuretic and ACE
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Figure 1: Recommendations for the diagnosis of heart failure
Figure 2:  Algorithm for the pharmacological treatment of symptomatic heart failure
due to left ventricular systolic dysfunction
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inhibitor therapy regardless of whether symptoms persist
or not.
• Diuretics should be routinely used for the relief of congestive
symptoms and fluid retention in patients with heart failure.
• Spironolactone should be considered in patients who remain
moderately to severely symptomatic despite optimal
therapy.
• Digoxin should be considered if a patient in sinus rhythm
remains symptomatic despite therapy with a diuretic, ACE
inhibitor (or angiotensin II receptor antagonist) and beta-
blocker or if the patient is in atrial fibrillation in which case
it is used as first-line therapy.
Follow-up
• All patients with chronic heart failure require monitoring.
• This should consist of a clinical assessment of functional
capacity, fluid status, cardiac rhythm, a review of
medication, serum urea, electrolytes and creatinine.
• Frequency of monitoring depends on clinical condition but
should not exceed 6 months.
Methods
We conducted a retrospective audit of the management of
heart failure at St. Luke’s Hospital.  The records of all patients
admitted to the medical wards in January 2002 were obtained
and those patients with a primary or secondary diagnosis of
heart failure were considered eligible for the purposes of the
audit.  Patients who had passed away by the time of the audit
and those patients whose files were untraceable were excluded
from the analysis.  Data from the files was entered in a pre-
prepared data sheet (Figure 3).  Demographic data about the
patient, investigations performed to reach the diagnosis and
assess severity, management of heart failure (both
pharmacological and non-pharmacological), and planned
follow-up were recorded on the data sheet.
Four hundred and thirty-nine case notes were requested of
which 72 could not be traced, 184 patients had died and 183
case notes were found, of which 97 satisfied the criteria and
were entered into the audit.
The diagnosis of congestive heart failure depended on either
presentation to Accident and Emergency Department with signs
and symptoms suggestive of heart failure or a note in the medical
history listing congestive heart failure as a concurrent medical
condition.
A total of 97 patients were included in the study and their
characteristics are shown in Table 1.
The male-to-female ratio was close to 1:1 with 47 males and
50 females.  As expected the females had a slightly higher mean
age at 77 years compared to a mean age of 74 years for males.
We looked at the incidence of the following co-morbid
conditions: ischaemic heart disease (35 patients), hypertension
(46 patients), diabetes mellitus (38 patients), chronic
obstructive pulmonary disease (30 patients), chronic renal
failure (27 patients), peripheral vascular disease (4 patients),
anaemia (2 patients) and gout (2 patients). There were 9
smokers, 29 ex-smokers and 59 non-smokers.
The aim of the audit was to assess the management of
patients suffering from congestive heart failure in SLH during
admission and follow-up.  We compared current practice with
the NICE recommendations.
Figure 3: Form used for data collection
Table 1: Baseline characteristics of the patients (n=97)
Characteristic Number
Gender
Males 47
 Age Range: 54 - 91 years
  Mean: 74 years
Females 50
  Age Range: 57 - 93 years
  Mean: 77 years
Smoking Status
Smokers 9
Ex-smokers 29
Non-smokers 59
Co-morbid conditions
Ischaemic heart disease 35
Hypertension 46
Diabetes mellitus 38
Chronic obstructive-pulmonary disease 30
Chronic renal failure 27
Peripheral vascular disease 4
Anaemia 2
Gout 2
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Results and Discussion
Diagnosis
The guidelines suggest that when a diagnosis of heart failure
is considered, a 12-lead ECG and / or natriuretic peptides should
be measured.  When one or both are abnormal, the diagnosis
should be confirmed by echocardiography.  Furthermore,
diseases that may present in a similar fashion should be excluded
by the tests shown in Figure 1.
Most patients did not have the full range of investigations
suggested by NICE (Table 2).
In fact although electrocardiography, a chest radiograph and
assays for urea, electrolytes, creatinine and a full blood count
were performed in all patients, the use of other tests was rather
low.  Eighty-seven percent of patients had a blood glucose
assessment, 36% liver function tests, 24% thyroid function, 13%
urine analysis, 8% lipid profile and none had spirometry.
Echocardiography, for the purpose of these guidelines serves
as a diagnostic tool to confirm the diagnosis of chronic heart
failure and exclude other pathologies.  The guidelines only
specify the need for a single echocardiogram; follow-up studies
are not mentioned.  The number of patients who had ever had
an echocardiogram for any reason was 28% with the dates of
tests going back up to 11 years previously.
B-type natriuretic peptide is a neurohormone secreted from
the cardiac ventricles in response to volume expansion and
pressure overload.  It has been shown to be highly sensitive as a
test to rule out chronic heart failure - a normal assay being very
unlikely even in a patient with asymptomatic heart failure.  The
test is not available at St. Luke’s Hospital so none of our patients
had this assayed.
Treatment
A diagrammatic representation of the algorithm for the
pharmacological treatment of symptomatic heart failure is
shown in Figure 2.
Our audit showed that only 2% of patients had lifestyle
modification advice documented in the case notes.  While some
degree of lifestyle modification advice is possibly given to most
patients, this analysis shows failure to deliver documented
standardised recommendations in 98% of patients.
Ninety-eight per cent of patients were treated with diuretics,
bumetanide being the most common. The dose ranged from 1mg
to 10mg daily in divided doses.  Two patients were on frusemide,
1 on bendrofluazide and 4 patients were having both bumetanide
and bendrofluazide.
All chronic heart failure patients should be on an ACE
inhibitor.  The only absolute contra-indications are anuria or
angioedema with previous exposure to the drug, bilateral renal
artery stenosis, pregnancy and cardiogenic shock.  In our patient
cohort 70 were on an ACE inhibitor.  Out of the remaining 28
patients, 2 were on an angiotension II receptor blocker, 2 had
elevated creatinine levels below 200 µmol/L, 1 had peripheral
vascular disease which may raise concerns on renal artery
stenosis and 3 had creatinine levels above 200 µmol/L but below
300µmol/L.  The guidelines advise caution in the use of ACE
inhibitors in patients with serum creatinine above 200µmol/L.
They recommend monitoring electrolytes and creatinine with
discontinuation only if potassium rises above 6mmol/L or
creatinine increases by more than 100% or above 350µmol/L.
Seventy-four per cent of patients treated for heart failure
were given either an ACE inhibitor or an angiotensin II receptor
blocker.  Twenty-five patients were not given either treatment,
with 6 possible contra-indications as outlined above (in only
one case was there documentation in the case notes).  It was
not clear why the other 19 patients were not being given this
treatment.
Enalapril was used in 64 of the 70 patients treated with ACE
inhibitors. NICE recommends that this should be started off at
a dose of 2.5 mg bd, which is then doubled every second week
until the maximum tolerated dose or the target dose of
10-20 mg bd is reached.  Figure 4 shows the dosage distribution
of enalapril in our patient cohort.  It is evident that the doses
used are less than those recommended with the mean dose being
9mg dly, less than half the target dose.  Only 6 patients are being
treated at target doses.  In spite of the low doses being used,
dosage was increased in only 9% of outpatient visits.
Table 2: Percentage of patients undergoing
recommended tests
Investigation % of patients
Echocardiography 28
BNP* 0
ECG 100
Chest X-Ray 100
Urea, electrolytes and creatinine 100
Full blood count 100
Plasma Glucose 87
Liver Function 36
Thyroid Function 24
Urinalysis 13
Lipids 8
Spirometry 0
 *BNP is B-type natriuretic peptide, a marker of ventricular
dysfunction.  Assay currently not available at SLH
Figure 4: Dosage distribution of enalapril
in study population
Daily dose enalapril (mg)
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Beta blockers are recommended in all patients with heart
failure due to left ventricular systolic dysfunction after diuretic
and ACE inhibitor therapy regardless of whether symptoms
persist or not.
Three large mortality trials have clearly demonstrated
favourable outcomes with beta-blocker use in patients with heart
failure using carvedilol, metoprolol and bisoprolol.7,8,9  At the
time of submission, only carvedilol and bisoprolol were licensed
in the UK for use in heart failure.
Our audit showed that only 9 patients were on beta-blocker
therapy (7 on carvedilol, 1 on atenolol and 1 on sotalol).  In our
study population there were 30 patients with chronic obstructive
pulmonary disease or asthma and 4 patients suffering from
peripheral vascular disease.  Beta-blockers are contra-indicated
in reversible airways disease although a cardio-selective beta-
blocker can be used with adequate caution.  Peripheral vascular
disease is not a contra-indication to prescription of a beta-
blocker.  Excluding pulmonary disease patients, 13% of eligible
patients were on a beta-blocker.  In none of the other cases was
documentation found in the patients’ notes of a reason as to
why beta blockade was not started.
NICE recommends that patients already on a beta-blocker
for some other reason be kept on the same medication.  Due to
the initial deterioration in cardiac function after starting beta-
blockade, these drugs should be commenced when the clinical
condition is stable.
Spironolactone has been shown to increase life expectancy
in moderate to severe heart failure.10  Twelve patients were on
spironolactone.  Unfortunately it proved very difficult to
determine baseline severity of heart failure from the notes as
NYHA class is infrequently documented.  We therefore cannot
comment on whether this drug is being under-utilised.
Follow-up
NICE suggest that all patients with heart failure should have
regular follow-up visits.  The range between visits should depend
on the clinical status of the patient, though the maximum
interval should be of 6 months.  In our audit we found that 55%
of patients had outpatient follow up visits.  The interval between
appointments ranged from 1 to 12 months.  Due to frequent
usage of vague terms such as, “first available MOP”, it was not
possible to determine mean interval between visits.
Conclusions and Recommendations
The analysis performed by us has a number of limitations.
It is a retrospective analysis of the management of patients prior
to the publication of the guidelines that we used as a gold
standard. Most of the evidence on which the guidelines were
based had been previously published, and the use of certain
drugs already formed part of daily medical practice although
their optimal use may have been less widespread.
At St. Luke’s Hospital there are logistic difficulties in
requesting certain tests such as echocardiograms,
notwithstanding the fact that 300 echocardiograms are
performed every month.  This may not necessarily mean that
the clinician is unacquainted with their importance.
Patients who had passed away by the time of the study were
excluded as it would be problematic to analyse the adequacy of
their follow-up.  On the other hand this introduces a bias in our
study population since it is difficult to determine whether  sub-
optimal treatment could have contributed to their death.
Despite the limitations of our audit, which was aimed at
getting an overview of current management practice, we suggest
that the diagnosis of heart failure should be reassessed in all
patients, their notes should be checked and any investigations
that need to be done should be carried out as per NICE
guidelines. One investigation that should be more frequently
used is echocardiography which is currently being done in less
than one third of patients.
While 75% of patients are on ACE inhibitors or angiotensin
II receptor antagonists, target doses should be attained and
more emphasis needs to be placed on incrementing medication
at each outpatient visit with a view to reaching maximal tolerated
doses.  After numerous trials showing the beneficial effects of
beta-blockers, their use in the local setting is definitely sub-
optimal.
Follow-up should be more consistent and frequent.  The
involvement of primary care physicians could serve to cut down
on hospital out-patient waiting lists and help to optimise patient
care.
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